Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials

Publication date: February 2017
Source:Auris Nasus Larynx, Volume 44, Issue 1
Author(s): Alvaro Sanabria, Aline L.F. Chaves, Luiz P. Kowalski, Gregory T. Wolf, Nabil F. Saba, Arlene A. Forastiere, Jonathan J. Beitler, Ken-ichi Nibu, Carol R. Bradford, Carlos Suárez, Juan P. Rodrigo, Primož Strojan, Alessandra Rinaldo, Remco de Bree, Missak Haigentz, Robert P. Takes, Alfio Ferlito
BackgroundThe primary goal of treatment in advanced laryngeal cancer is to achieve optimal oncologic outcomes while preserving function and quality of life. Combination of chemotherapy and radiation has been popularized as an alternative to surgery for patients facing total laryngectomy. However, survival analyses from large, population-based databases have not duplicated results reported from randomized trials.MethodsA comprehensive literature review was undertaken to try to better understand the reasons why results differ among randomized trials and population cohort studies.ResultsA variety of reasons are discussed, including differences in patient staging, selection bias, complexity bias, inconsistent terminology, patient compliance and treatment expertise.ConclusionsPersonalized treatment considering all factors is critical for optimal outcomes. In general, evidence supports total laryngectomy for patients with T4 cancers. Definitive chemoradiotherapy strategies are acceptable alternatives for T3 cancers, provided that all resources for the administration of the treatment, follow-up and surgical salvage are available.



http://ift.tt/2klRsmu